Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies,in the treatment of primary immune thrombocytopenia

Prabhu, Mukhyaprana (2012) Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies,in the treatment of primary immune thrombocytopenia. Blood, 120 (18). pp. 3670-3676. ISSN 0006-4971

[img] PDF
Rozrolimupab_Blood_2012.pdf - Published Version
Restricted to Registered users only

Download (292kB) | Request a copy

Abstract

Rozrolimupab, a recombinant mixture of 25 fully human RhD-specific monoclonal antibodies, represents a new class of recombinant human antibody mixtures. In a phase 1 or 2 dose escalation study, RhD(+) patients (61 subjects) with primary immune thrombocytopenia received a single intravenous dose of rozrolimupab ranging from 75 to 300 μg/kg. The primary outcome was the occurrence of adverse events. The principal secondary outcome was the effect on platelet levels 7 days after the treatment. The most common adverse events were headache and pyrexia, mostly mild, and reported in 20% and 13% of the patients, respectively, without dose relationship. Rozrolimupab caused an expected transient reduction of hemoglobin concentration in the majority of the patients. At the dose of 300 μg/kg platelet responses, defined as platelet count ≥ 30 × 10(9)/L and an increase in platelet count by > 20 × 10(9)/L from baseline were observed after 72 hours and persisted for at least 7 days in 8 of 13 patients (62%). Platelet responses were observed within 24 hours in 23% of patients and lasted for a median of 14 days. Rozrolimupab was well tolerated and elicited rapid platelet responses in patients with immune thrombocytopenia and may be a useful alternative to plasma-derived products. This trial is registered at www.clinicaltrials.gov as #NCT00718692.

Item Type: Article
Subjects: Medicine > KMC Manipal > Medicine
Depositing User: KMC Manipal
Date Deposited: 19 Jan 2013 10:58
Last Modified: 19 Jan 2013 10:58
URI: http://eprints.manipal.edu/id/eprint/78046

Actions (login required)

View Item View Item